Acquisitions - Additional Information (Details) € in Millions, $ in Millions											1 Months Ended	3 Months Ended		6 Months Ended	12 Months Ended
		Mar. 01, 2016 USD ($)	Jan. 22, 2016 USD ($)	Dec. 15, 2015 USD ($)	Sep. 15, 2015 USD ($)	Sep. 15, 2015 EUR (€)	Aug. 28, 2015 USD ($)	May 12, 2015 USD ($)	Mar. 30, 2015 USD ($) shares	Mar. 30, 2015 EUR (€) shares	May 31, 2015 USD ($) product	Apr. 02, 2016 USD ($)	Mar. 28, 2015 USD ($)	Dec. 31, 2015 USD ($) products	Dec. 31, 2015 USD ($) products	Jun. 27, 2015 USD ($) shares	Dec. 02, 2014 USD ($)	Nov. 08, 2013 USD ($)
Business Acquisition [Line Items]
Research and development expense												$ 45.3	$ 35.4
Senior notes												5,937.1		$ 4,698.3	$ 4,698.3			$ 2,300.0
Operating income (loss)												(231.6)	$ 190.4
Tretinoin Products
Business Acquisition [Line Items]
Acquisition date			Jan. 22, 2016
Purchase price paid	[1]		$ 416.4
Contingent consideration	[1]		$ 0.0
Net sales												15.9
Operating income (loss)												$ 11.4
Tretinoin Products | Developed product technology, formulations, and product rights
Business Acquisition [Line Items]
Intangible assets weighted average useful life			20 years
Tretinoin Products | Non-compete agreements
Business Acquisition [Line Items]
Intangible assets weighted average useful life			5 years
Development-Stage Rx Products
Business Acquisition [Line Items]
Acquisition date		Mar. 01, 2016
Purchase price paid	[1]	$ 0.0
Contingent consideration	[1]	$ 29.5
Development-Stage Rx Products | Minimum
Business Acquisition [Line Items]
Business Combination, Contingent Consideration, Royalty Payment Period		7 years
Development-Stage Rx Products | Maximum
Business Acquisition [Line Items]
Business Combination, Contingent Consideration, Royalty Payment Period		10 years
Development-Stage Rx Products | Contractual arrangement
Business Acquisition [Line Items]
Research and development expense											$ 18.0
Business acquisitions, number of products purchased | product											2
Entocort®
Business Acquisition [Line Items]
Acquisition date				Dec. 15, 2015
Purchase price paid				$ 380.2
Contingent consideration				$ 0.0
Entocort® | Minimum | Developed product technology, formulations, and product rights
Business Acquisition [Line Items]
Intangible assets weighted average useful life				10 years
Entocort® | Maximum | Developed product technology, formulations, and product rights
Business Acquisition [Line Items]
Intangible assets weighted average useful life				15 years
Naturwohl
Business Acquisition [Line Items]
Acquisition date					Sep. 15, 2015	Sep. 15, 2015
Purchase price paid					$ 150.4
Contingent consideration					$ 0.0
Percentage of interests acquired					100.00%
Naturwohl | Non-compete agreements
Business Acquisition [Line Items]
Intangible assets weighted average useful life					3 years	3 years
Naturwohl | Trademarks, trade names, and brands
Business Acquisition [Line Items]
Intangible assets weighted average useful life					20 years	20 years
Naturwohl | Customer relationships and distribution networks
Business Acquisition [Line Items]
Intangible assets weighted average useful life					15 years	15 years
Naturwohl | Distribution and license agreements, supply agreements
Business Acquisition [Line Items]
Intangible assets weighted average useful life					3 years	3 years
Naturwohl | Euro
Business Acquisition [Line Items]
Purchase price paid | €						€ 133.5
ScarAway®
Business Acquisition [Line Items]
Acquisition date							Aug. 28, 2015
Purchase price paid							$ 26.7
Contingent consideration							$ 0.0
ScarAway® | Developed product technology, formulations, and product rights
Business Acquisition [Line Items]
Intangible assets weighted average useful life							8 years
ScarAway® | Non-compete agreements
Business Acquisition [Line Items]
Intangible assets weighted average useful life							4 years
ScarAway® | Trademarks, trade names, and brands
Business Acquisition [Line Items]
Intangible assets weighted average useful life							25 years
ScarAway® | Customer relationships and distribution networks
Business Acquisition [Line Items]
Intangible assets weighted average useful life							15 years
GSK Products
Business Acquisition [Line Items]
Acquisition date							Aug. 28, 2015
Purchase price paid							$ 223.6
Contingent consideration							$ 0.0
GSK Products | Trademarks, trade names, and brands
Business Acquisition [Line Items]
Intangible assets weighted average useful life							20 years
GSK Products | Customer relationships and distribution networks
Business Acquisition [Line Items]
Intangible assets weighted average useful life							15 years
GSK Products | Euro
Business Acquisition [Line Items]
Purchase price paid							$ 200.0
Gelcaps
Business Acquisition [Line Items]
Acquisition date								May 12, 2015
Purchase price paid								$ 37.9
Contingent consideration								$ 0.0
Percentage of interests acquired								100.00%
Gelcaps | Trademarks, trade names, and brands
Business Acquisition [Line Items]
Intangible assets weighted average useful life								25 years
Gelcaps | Customer relationships and distribution networks
Business Acquisition [Line Items]
Intangible assets weighted average useful life								20 years
Gelcaps | Inventory
Business Acquisition [Line Items]
Inventory adjustment								$ 0.6
Gelcaps | Property, plant and equipment
Business Acquisition [Line Items]
Property, plant and equipment adjustment								$ 0.9
Restated Omega
Business Acquisition [Line Items]
Acquisition date									Mar. 30, 2015	Mar. 30, 2015
Purchase price paid									$ 2,983.2
Intangible assets weighted average useful life									20 years 7 months 6 days	20 years 7 months 6 days
Contingent consideration									$ 0.0
Percentage of interests acquired									95.77%
Shares outstanding (in shares) | shares									685,348,257
Treasury stock (in shares) | shares									30,243,983	30,243,983
Proceeds from stock issuance																$ 999.3
Restated Omega | Non-compete agreements
Business Acquisition [Line Items]
Intangible assets weighted average useful life									3 years	3 years
Restated Omega | Trademarks, trade names, and brands
Business Acquisition [Line Items]
Intangible assets weighted average useful life									8 years	8 years
Restated Omega | Customer relationships and distribution networks
Business Acquisition [Line Items]
Intangible assets weighted average useful life									21 years	21 years
Restated Omega | Non-solicit agreement
Business Acquisition [Line Items]
Intangible assets weighted average useful life									2 years	2 years
Restated Omega | Brands
Business Acquisition [Line Items]
Intangible assets weighted average useful life									22 years	22 years
Restated Omega | Minimum | Developed product technology, formulations, and product rights
Business Acquisition [Line Items]
Intangible assets weighted average useful life									4 years	4 years
Restated Omega | Maximum
Business Acquisition [Line Items]
Indemnification available from acquired company's sellers | €										€ 277.0
Restated Omega | Maximum | Developed product technology, formulations, and product rights
Business Acquisition [Line Items]
Intangible assets weighted average useful life									13 years	13 years
Restated Omega | Euro | Maximum
Business Acquisition [Line Items]
Indemnification available from acquired company's sellers									$ 248.0
Restated Omega | Inventory
Business Acquisition [Line Items]
Inventory adjustment									15.1
Restated Omega | Property, plant and equipment
Business Acquisition [Line Items]
Property, plant and equipment adjustment									41.5
Restated Omega | Debt
Business Acquisition [Line Items]
Business combination fair value adjustment									$ 101.9
Restated Omega | 2014 bonds
Business Acquisition [Line Items]
Senior notes																	$ 1,600.0
Restated Omega | Ordinary shares
Business Acquisition [Line Items]
Stock issued (in shares) | shares																6,800,000
All Other
Business Acquisition [Line Items]
Purchase price paid	[2]														15.3
Contingent consideration	[2]													$ 13.9	$ 13.9
Business acquisitions, number of products purchased | products														8	2

[1] * Opening balance sheet is preliminary

[2] Consists of eight product acquisitions in our CHC, BCH and Rx segments.